These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 1475450)

  • 1. [Cytosol concentrations of CAM29 in breast carcinoma. Effect of the pS2].
    Suárez B; Fernández Llana B; Allende MT; Ruibal A
    Rev Clin Esp; 1992 Oct; 191(5):284. PubMed ID: 1475450
    [No Abstract]   [Full Text] [Related]  

  • 2. [The cytosolic concentrations of CAM26 and CAM29 in breast tumors classified according to the clinical stage].
    Fernández M; Suárez B; González C; Allende MT
    Rev Clin Esp; 1992 May; 190(9):480-1. PubMed ID: 1626101
    [No Abstract]   [Full Text] [Related]  

  • 3. CAM26 and CAM29 cytosol levels in breast tumors classified according to estrogen receptor status. First results.
    Suarez B; González C; Allende MT; Fernández Fernández M; Fernández Llana B; Roiz MC; Vizoso F; Ruibal A
    Int J Biol Markers; 1992; 7(2):126-8. PubMed ID: 1634825
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of immunohistochemical markers in the diagnosis of carcinoma of the breast].
    Bussolati G
    Minerva Chir; 1988 Sep; 43(18 Suppl):5-7. PubMed ID: 3226595
    [No Abstract]   [Full Text] [Related]  

  • 5. CAM26 cytosol levels seem to be correlated with pS2 expression in breast cancer.
    Fernandez Fernandez M; Fernandez Llana B; Fernandez Raigoso P; Roiz MC; Allende MT; Ruibal A
    Int J Biol Markers; 1993; 8(1):25-6. PubMed ID: 8496628
    [No Abstract]   [Full Text] [Related]  

  • 6. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects.
    Tuccari G; Rizzo A; Muscarà M; Giuffrè G; Barresi G
    Pathologica; 1993; 85(1095):47-55. PubMed ID: 8100059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor markers in human breast cancer].
    Takami H; Shikata J
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):2998-3003. PubMed ID: 3479050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luminal B breast tumors are not HER2 positive.
    Bhargava R; Dabbs DJ
    Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract]   [Full Text] [Related]  

  • 9. [Mucoid carcinoma antigen--a new tumor marker].
    Bieglmayer C; Szepesi T; Neunteufel W
    Gynakol Rundsch; 1988; 28 Suppl 2():203-5. PubMed ID: 3234919
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
    Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
    Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
    [No Abstract]   [Full Text] [Related]  

  • 11. An evaluation of the usefulness of primary tumour expression of MCA and CA15-3 as prognostic indicators in breast carcinoma.
    Byrne J; Horgan PG; England S; Callaghan J; Given HF
    Eur J Surg Oncol; 1992 Jun; 18(3):230-4. PubMed ID: 1607033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Male breast cancer. Histochemical and flow cytometry analysis of 6 cases].
    Galasso MG; Galia A; Gazzano G; Cosentino A; Castorina S
    Pathologica; 1995 Oct; 87(5):503-5. PubMed ID: 8868175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnostic pitfalls in mammary pathology. Case 8. Breast metastases of a malignant melanoma].
    Dauplat MM; Penault-Llorca F
    Ann Pathol; 2009 Jun; 29(3):228-32. PubMed ID: 19619831
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunohistochemical tumor diagnosis in breast cancer--use for assessing the stage and biology of so-called "small breast cancer"].
    Schauer A; Rothe H; Balzer I; Fiebig I; Rauschecker H
    Rontgenblatter; 1988 Aug; 41(8):340-4. PubMed ID: 3064267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of prostate-specific antigen (PSA) in cytosol of breast tumors and human endometrium--new diagnostic approaches].
    Seliger E; Kaltwasser P; Röpke F
    Zentralbl Gynakol; 1998; 120(4):172-5. PubMed ID: 9610520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A checklist for suitability of biomarkers as surrogate endpoints in chemoprevention of breast cancer.
    Bogoch S; Bogoch ES
    J Cell Biochem Suppl; 1994; 19():173-85. PubMed ID: 7823589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of different estrogen receptor forms in breast cancer cytosol by enzyme immunoassay.
    Dittadi R; Meo S; Amoroso B; Gion M
    Cancer Res; 1997 Mar; 57(6):1066-72. PubMed ID: 9067273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunohistochemical detection of bcl-2 and MIB-1/Ki-67 in breast cancer: retrospective analysis of 238 cases].
    Sundlad AS; Ahn C; Battifora H
    Medicina (B Aires); 1996; 56(3):252-8. PubMed ID: 9035481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of the estrogen and progesterone receptor content of primary breast cancers without skeletal or visceral metastasis with tumor marker MCA, CEA and CA 15-3 serum concentration at the time of surgery].
    Seifert M; Wierrani F; Kubista E; Spona J
    Gynakol Rundsch; 1991; 31 Suppl 2():397-8. PubMed ID: 1790992
    [No Abstract]   [Full Text] [Related]  

  • 20. [Place of carbohydrate antigens in the spectrum of protein tumor markers in patients with tumors at different sites].
    Reznikov IuP; Ul'ianov VI; Variukhin AS; Vanin AI; Vorontsova LP
    Vopr Onkol; 1988; 34(1):51-6. PubMed ID: 3422524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.